Abstract A50: Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk early breast cancer patients in the I-SPY 2 TRIAL

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Magbanua, MJM; Li, W; Wolf, DM; Yau, C; Hirst, GL; Brown-Swigart, L; Chien, AJ; Delson, AL; Gibbs, J; Aleshin, A; Zimmerman, B; Esserman, L; Hylton, N; Veer, LVT

Published Date

  • June 1, 2020

Published In

  • Poster Presentations Proffered Abstracts

Published By

Digital Object Identifier (DOI)

  • 10.1158/1557-3265.liqbiop20-a50

Conference Name

  • Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL